You can't seriously imagine GSK could BTA by paying $2.35/share do you? Who would agree to that? A takeover premium would price it closer to $12 with all the associated hype around vastly increased demand for Relenza, LANI and other BTA blue sky projects. I also doubt Costello would wear it given adverse publicity surounding the court case and Sankyo would be highly resistant as a JV partner.
Add to My Watchlist
What is My Watchlist?